Upfront Diagnostics, a medtech company based in Cambridge, UK, has successfully raised $669,576 from investors. Established in 2017, the company is focused on commercialising the LVOne, which it describes as the first rapid blood test for strokes. Its core mission is to revolutionise emergency stroke care by discovering and applying novel biomarkers designed to help medical professionals deliver more effective and cost-efficient care solutions. This secured investment underscores confidence in Upfront Diagnostics' approach to addressing critical needs in neurological diagnostics.
This funding round marks a pivotal moment for Upfront Diagnostics as it progresses towards market entry and global commercialisation. The company has demonstrated significant progress, with the high performance of its LVOne test validated through multiple clinical studies, and it is actively involved in trials worldwide. Further reinforcing its readiness, Upfront Diagnostics is an ISO 13485 certified company and has achieved manufacturing readiness, positioning it for scalable market introduction of its diagnostic technology.
The newly secured capital will be strategically deployed to support Upfront Diagnostics' ambitious growth initiatives. These plans include accelerating the commercialisation pathway for the LVOne, ensuring its broader availability to healthcare providers. Additionally, the investment is expected to facilitate continued research and development efforts in the discovery and application of further novel biomarkers. Upfront Diagnostics aims to solidify its position at the forefront of stroke diagnostics, ultimately contributing to improved patient outcomes globally through accessible and rapid testing.
